Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Boston Therapeutics, Inc. (BTHE) Tackles One of America’s Greatest Epidemics

It’s turning out to be one of the biggest epidemic waves in American history, with estimated costs nationally jumping approximately 40% in just the past 5 years, to roughly $1/4 trillion annually. The epidemic is diabetes, and the size and scope of the problem, including the disastrous drain on the country’s economy, is just now beginning to be fully appreciated. Less obvious and dramatic than high-profile diseases such as cancer, the hidden power behind the diabetes epidemic is that it affects so many people. It is now estimated that over 25 million Americans have the disease, though many are not aware of it, with nearly 80 million Americans in a state of prediabetes. Diabetes complications include heart disease, stroke, kidney damage, and retinopathy.

Driven, it is believed, by a generation of negative dietary and life style habits, diabetes is now becoming one of America’s primary healthcare targets. Unfortunately, such habits, and the industries that support them, are slow to change, and today there is a desperate need for medical technologies that can help stem the epidemic tide more quickly.

Boston Therapeutics believes it has developed the most effective single solution with PAZ320, the company’s non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. The drug is currently undergoing clinical trials after getting promising results in initial studies. PAZ320 would be a miracle to millions of diabetic and prediabetic patients, or anyone seeking to better manage blood glucose levels, by inhibiting the enzymes that release glucose from complex carbohydrates in foods during digestion. As a result, the drug now has a near-term opportunity in what is already a $35 billion diabetes drug market.

PAZ320 is not Boston Therapeutic’s only product. They are also in pre-clinical stage development of IPOXYN, an injectable universal oxygen carrier for the prevention of necrosis and treatment of ischemic conditions which may lead to necrosis, and OxyFex, a veterinary facsimile to Ipoxyn.

For additional information, visit

Let us hear your thoughts below:

This entry was posted in Boston Therapeutics Inc. BTHE. Bookmark the permalink.

Comments are closed.